FDA Approves Aducanumab for Alzheimer's Disease

The U.S. Food and Drug Administration (FDA) today approved aducanumab (Biogen/Eisai) to treat Alzheimer’s disease.

This is the first drug that slows Alzheimer’s disease. And, this is the beginning of a completely new future for Alzheimer’s treatments. This is a new type of Alzheimer’s treatment; it addresses the disease in a way that has never been done before, compared to currently approved drugs.

Alzheimer’s — a progressive, degenerative and fatal brain disease — is the most common cause of dementia. For Alzheimer’s Disease Facts and Figures, an annual report by the Alzheimer’s Association,...